Straits Times Index
3,325.58 -0.70 (-0.02%) Nikkei
39,750.50 +577.35 (+1.47%) Hang Seng
18,075.05 +2.15 (+0.01%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,780.41 +598.86 (+0.98%) CMC Crypto 200
1,284.29 +35.16 (+2.81%)
ARGX Dec 2024 430.000 call
- GlobeNewswire
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which is FDA approved for use in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) June 25, 2024 – 4:30pm EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company
- Zacks
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- Zacks
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
